Is vitamin D prescribed for migraine prophylaxis?

Vitamin D for Migraine Prophylaxis

Vitamin D is not a first-line or guideline-recommended preventive medication for migraine, but emerging evidence suggests it may be prescribed as an adjunctive or alternative option, particularly in patients with documented vitamin D deficiency.

Guideline-Based First-Line Recommendations

The established first-line preventive agents for migraine remain propranolol (80-240 mg/day), timolol (20-30 mg/day), amitriptyline (30-150 mg/day), divalproex sodium (500-1500 mg/day), and sodium valproate (800-1500 mg/day) 1, 2. The most recent 2025 ACP guideline reaffirms these traditional agents as the standard of care 3. Vitamin D is notably absent from all major clinical practice guidelines for migraine prevention [@1-12@].

Evidence for Vitamin D in Migraine

Despite the absence of guideline endorsement, recent research provides compelling data:

Association Studies

• Vitamin D deficiency (serum 25(OH)D <20 ng/mL) is highly prevalent in migraine patients (65-88%), particularly in chronic migraine (80-92%) 4
• Migraineurs have significantly lower serum vitamin D levels than non-migraineurs (mean difference -4.44 ng/mL) 5
• Hypovitaminosis D is associated with nearly 2-fold increased odds of migraine (OR: 1.95) 5
• Lower vitamin D levels correlate with higher migraine frequency, severity, and disability scores 6, 7

Intervention Studies

The most robust evidence comes from recent meta-analyses:

• Vitamin D supplementation significantly reduces monthly migraine frequency by 2.20-2.74 attacks 5, 8, 9
• Headache days per month decrease by 1.56 days 9
• Migraine Disability Assessment (MIDAS) scores improve significantly 8, 9
• High-dose vitamin D (≥50,000 IU/week) reduces migraine attacks by 50-72% in deficient adults 4

However, these benefits appear most pronounced in vitamin D-deficient patients, with minimal benefit in those with replete levels 4.

Clinical Algorithm for Vitamin D Use in Migraine

When to Consider Vitamin D:

1. After establishing first-line preventive therapy per guidelines 1, 2, 3
2. In patients with documented vitamin D deficiency (serum 25(OH)D <20 ng/mL)
3. As adjunctive therapy in patients with inadequate response to standard preventives
4. In patients with contraindications to or intolerance of first-line agents

Dosing Strategy:

• Check baseline serum 25(OH)D level before initiating therapy 4
• For deficient patients: 50,000 IU every 2 weeks (as used in recent trials) 10, 11
• For maintenance: 2,000 IU (50 μg) daily 6
• Recheck levels after 12 weeks to guide continuation 10, 6

Expected Outcomes:

• Clinical benefit may take 8-12 weeks to manifest 6, 11
• Greatest reduction in attack frequency and severity occurs in those with baseline deficiency 4
• Minimal adverse effects compared to traditional preventives 5, 8

Important Caveats

The evidence for vitamin D remains lower quality than for guideline-recommended agents - most studies are small, single-center trials with heterogeneous populations 5, 8, 9. The 2002 guideline mentions only "fair evidence for modest efficacy" of supplements like magnesium and riboflavin, with vitamin D not specifically addressed 1.

Vitamin D should not replace proven first-line therapies but may be considered as:

• An adjunct to standard preventives
• A trial in patients who have failed multiple first-line agents
• Primary prevention in those with documented deficiency and contraindications to standard agents

Combination Therapy

Emerging evidence suggests enhanced efficacy when vitamin D is combined with:

• Probiotics (4.5 × 10¹¹ CFU/day): greater reduction in migraine index and frequency 10, 11
• Topiramate: potential benefit in refractory cases 4

Practical Implementation

Screen for vitamin D deficiency in migraine patients, particularly those with:

• Chronic migraine (≥15 headache days/month)
• High-frequency episodic migraine
• Inadequate response to first-line preventives
• Geographic location >40°N latitude 4

If deficiency is confirmed, supplementation is reasonable as part of a comprehensive migraine management strategy, but should not delay initiation of guideline-recommended preventive medications 1, 2, 3.

The FDA-approved indication for vitamin D is for vitamin D deficiency and related conditions (rickets, hypoparathyroidism, renal osteodystrophy), not migraine prevention 12. Its use for migraine remains off-label but is supported by growing clinical trial evidence 5, 8, 9, 6.